Cargando…

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy

BACKGROUND: Anti-GD2 monoclonal antibody immunotherapy has significantly improved the overall survival rate for high-risk neuroblastoma patients. However, 40% of patients fail to respond or develop resistance to treatment, and the molecular mechanisms by which this occurs remain poorly understood. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaoming, Wills, Carson A, Chen, Longgui, Zhang, Jiawen, Zhao, Yuanjun, Zhou, Mi, Sundstrom, Jeffrey M, Schell, Todd, Spiegelman, Vladimir S, Young, Megan M, Wang, Hong-Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052051/ https://www.ncbi.nlm.nih.gov/pubmed/35483745 http://dx.doi.org/10.1136/jitc-2021-004399

Ejemplares similares

Quantifying the impact of immunotherapy on RNA dynamics in cancer
por: Usaite, Ieva, et al.
Publicado: (2023)

Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy
por: Beyranvand Nejad, Elham, et al.
Publicado: (2020)

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
por: Beyranvand Nejad, Elham, et al.
Publicado: (2021)

Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy
por: Cubas, Rafael, et al.
Publicado: (2020)

Tumors establish resistance to immunotherapy by regulating T(reg) recruitment via CCR4
por: Marshall, Lisa A, et al.
Publicado: (2020)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy
por: Choudhury, Ruhul H, et al.
Publicado: (2022)

Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
por: Krieg, Carsten, et al.
Publicado: (2022)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer
por: Boelaars, Kelly, et al.
Publicado: (2023)

Leveraging the Treg-intrinsic CTLA4–PKCη signaling pathway for cancer immunotherapy
por: Liu, Hsin-Yu, et al.
Publicado: (2021)

Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation
por: Zhu, Lin, et al.
Publicado: (2022)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy
por: Bao, Xuanwen, et al.
Publicado: (2020)

An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy
por: Wang, Hui, et al.
Publicado: (2020)

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer
por: Cao, Xu, et al.
Publicado: (2021)

Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies
por: Lo, Amy A, et al.
Publicado: (2021)

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
por: Kalinovsky, Daniel V, et al.
Publicado: (2022)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
por: Chan, Godfrey Chi-Fung, et al.
Publicado: (2022)

Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance
por: Shi, Linlin, et al.
Publicado: (2020)

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
por: Lee, Maxwell Y, et al.
Publicado: (2021)

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy
por: Marcu, Ana, et al.
Publicado: (2021)

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021)

Combinatorial immunotherapy induces tumor-infiltrating CD8(+) T cells with distinct functional, migratory, and stem-like properties
por: Van Braeckel-Budimir, Natalija, et al.
Publicado: (2021)

Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy
por: van Elsas, Marit J, et al.
Publicado: (2023)

Implication of (99m)Tc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells
por: Gao, Yu, et al.
Publicado: (2023)

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells
por: Hussein, Brwa Ali, et al.
Publicado: (2023)

Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies
por: Odunsi, Adekunle, et al.
Publicado: (2020)

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
por: Lopes, Jared E, et al.
Publicado: (2020)

System analysis based on the cancer–immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma
por: Wang, Xu, et al.
Publicado: (2022)

Escherichia coli adhesin protein-conjugated thermal responsive hybrid nanoparticles for photothermal and immunotherapy against cancer and its metastasis
por: Hwang, Juyoung, et al.
Publicado: (2021)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
por: Molvi, Zaki, et al.
Publicado: (2023)

Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression
por: Finisguerra, Veronica, et al.
Publicado: (2023)

NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8(+) T cell responses capable of curing multi-focal cancer
por: Walker, Joshua M, et al.
Publicado: (2020)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
por: Paret, Claudia, et al.
Publicado: (2022)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Hubert, Pascale, et al.
Publicado: (2021)

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
por: Melchor, Javier, et al.
Publicado: (2023)

Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8(+) T cells
por: LaPorte, Kathryn M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vn89lo4m17ukpqdjf1c1ul9jpp